3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
25
Salivary Gland Neoplasms
2
Metastatic Castration-resistant Prostate Cancer
2
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Neoplasms
1
Neoplasm Metastasis
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Carcinoma, Intraductal, Noninfiltrating
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Cancer Female
1
Biochemically Recurrent Prostate Cancer
1
Interventions
darolutamide
1
Pluvicto
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
High-Risk Localized Prostate Cancer
×
darolutamide
×
Clear all
NCT07450599
2026-05-13
CHINANEO
Bayer
Phase 2
Recruiting
250 enrolled